ATRA - Atara Biotherapeutics, Inc.
| Previous Close | 21.43 |
| Open | 21.23 |
| Bid | 20.66 x 1000 |
| Ask | 20.69 x 800 |
| Day's Range | 20.17 - 21.50 |
| 52 Week Range | 20.17 - 43.95 |
| Volume | 279,535 |
| Avg. Volume | 683,180 |
| Market Cap | 959.767M |
| Beta (3Y Monthly) | 3.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.62 |
| Earnings Date | Nov 2, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.29 |
- Insider Monkey•19 hours ago
Were Hedge Funds Right About Flocking Into Atara Biotherapeutics Inc (ATRA) ?
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
- GlobeNewswire•19 days ago
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., June 05, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GlobeNewswire•20 days ago
Atara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
Memorial Sloan Kettering Cancer Center collaborators presented results demonstrating that a regionally delivered mesothelin-targeted, autologous CAR T was well tolerated and.
- American City Business Journals•21 days ago
Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO
Our latest Health Care Digest is taking names and targeting the latest in biotech and health care news.
- GlobeNewswire•23 days ago
Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 01, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GlobeNewswire•25 days ago
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 30, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GlobeNewswire•27 days ago
Atara Biotherapeutics Appoints Pascal Touchon President, Chief Executive Officer and Member of the Board of Directors
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the appointment of Pascal Touchon as President, Chief Executive Officer and member of the Board of Directors. Dr. Touchon has over 30 years of global biopharmaceutical leadership experience, most recently at Novartis Oncology serving as Global Head, Cell & Gene and member of the Oncology Executive Committee. Previously at Novartis, Pascal Touchon served as Global Head, Strategy, Business Development, Oncology where he was responsible for various activities including early commercial strategy, portfolio management, business development and external collaborations as well as member of the Oncology Executive Committee.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ATRA earnings conference call or presentation 9-May-19 12:30pm GMT
Q1 2019 Atara Biotherapeutics Inc Earnings Call
- GlobeNewswire•last month
Atara Biotherapeutics Announces Presentations Highlighting Tab-cel® and Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 15, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GlobeNewswire•last month
Atara Biotherapeutics Announces Presentation of Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)
SOUTH SAN FRANCISCO, Calif., May 15, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- Motley Fool•2 months ago
Why Atara Biotherapeutics Stock Is Imploding Today
Investors are growing impatient with this clinical-stage biotech.
- Associated Press•2 months ago
Atara Biotherapeutics: 1Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of $1.44 per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•2 months ago
Atara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress
SOUTH SAN FRANCISCO, Calif., May 09, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- ACCESSWIRE•2 months ago
Atara Biotherapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Atara Biotherapeutics, Inc. (NASDAQ: ATRA ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM ...
- GlobeNewswire•2 months ago
Atara Biotherapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019
SOUTH SAN FRANCISCO, Calif., May 07, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- Motley Fool•2 months ago
Where Will Gilead Sciences Spend Its Cash?
Atara Biotherapeutics and Exelixis might be top takeover targets for the biotech giant.
- Insider Monkey•2 months ago
Here is What Hedge Funds Think About Atara Biotherapeutics Inc (ATRA)
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent […]
- Motley Fool•2 months ago
2 Best Biotech Buyout Plays
Atara Biotherapeutics and Crispr Therapeutics stand out as strong takeover candidates. Here's why.
- GlobeNewswire•3 months ago
Atara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research (AACR) Annual Meeting 2019
Epstein-Barr virus-specific T cells were engineered to express second-generation CD19 chimeric antigen receptors, eliminated in vitro alloreactivity and inhibited tumor growth.
- GlobeNewswire•3 months ago
Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
Memorial Sloan Kettering Cancer Center collaborators presented results that a regionally delivered mesothelin-targeted, autologous CAR T was well-tolerated and showed.
- Simply Wall St.•4 months ago
The Atara Biotherapeutics (NASDAQ:ATRA) Share Price Has Gained 122%, So Why Not Pay It Some Attention?
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you canRead More...
- GlobeNewswire•4 months ago
Atara Biotherapeutics to Participate in Upcoming Conferences
SOUTH SAN FRANCISCO, Calif., March 07, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- American City Business Journals•4 months ago
How attacking a virus in cancer patients helped a Peninsula company target MS
Cancer remains the company's main focus, but it also is pushing to transform treatment of multiple sclerosis.
